Biotech and pharma brands have more distinct audiences than almost any other category, each needing a different case made in a different register, but most messaging gets flattened into one generic script that satisfies medical, legal, and regulatory review without persuading anyone.
The Problem
One messaging document tries to serve four audiences that need four different arguments
A clinician wants mechanism and evidence. A payer wants outcomes and cost offset. A patient wants what changes for them, in plain language. An investor wants market size and competitive differentiation. Most biotech and pharma companies write a single core messaging document and adapt it lightly for channel, when what's actually needed is a distinct argument built for each audience's real decision criteria, sharing a common factual foundation but not a common script.
Medical, legal, and regulatory review flattens messaging into safe but forgettable language
Necessary and appropriate review processes, given the category's real risk, tend to strip out anything that sounds like a claim without exhaustive substantiation, and the result is often technically accurate messaging that says nothing memorable or differentiated. Competitors facing the exact same review constraints somehow land sharper positioning, which means the constraint isn't actually the obstacle – the absence of a messaging framework built to survive review intact is.
Positioning gets defined by mechanism of action instead of the problem being solved
It's natural for a science-led organization to lead with how a therapy or platform works, but most buyers and stakeholders – payers, health system administrators, even many clinicians outside the immediate specialty – care first about what problem gets solved and for whom, with mechanism as supporting evidence rather than the headline. Mechanism-first messaging reads as credible to insiders and confusing to everyone else evaluating whether this matters to them.
Competitive differentiation gets asserted instead of demonstrated
Claims like "first-in-class" or "best-in-class" appear across messaging without the specific, defensible comparison points that would actually make a clinician, payer, or investor believe it. Without concrete points of difference tied to real clinical, operational, or commercial evidence, differentiation claims blend into the same undifferentiated noise every competitor is also producing.
How We Help
We start by mapping the distinct decision criteria for each of your real audiences – clinicians, payers, patients, investors, and any institutional buyers specific to your category – rather than starting from a single core message and adapting it. Each audience gets its own argument built around what they actually need to believe to act, sharing the same underlying facts but not the same framing or emphasis.
From there we build messaging designed to survive medical, legal, and regulatory review intact, working inside that review process rather than treating it as an obstacle to route around after the fact. That means grounding differentiated language in evidence specific enough to substantiate, so review has something concrete to approve instead of stripping vague claims down to nothing. We've found the sharpest messaging usually survives review better than the vague version, because specificity is easier to substantiate than generality dressed up as a claim.
We reposition the narrative around the problem being solved and for whom, with mechanism of action as supporting evidence rather than the opening argument. This shift alone often clarifies messaging significantly, because it forces a decision about which audience's problem the headline is actually addressing, instead of trying to explain the science to everyone at once.
Competitive differentiation gets built on specific, defensible comparison points – clinical trial design differences, delivery mechanism, health economic outcomes, real market gaps – rather than asserted superlatives. We work with your medical and commercial teams to identify what's genuinely different and evidence it clearly enough that a skeptical clinician or payer can verify the claim themselves rather than taking your word for it.
What we deliver
- Audience-specific messaging framework – distinct arguments for clinicians, payers, patients, and investors built on shared facts
- Review-resilient messaging – language grounded in specific, substantiable evidence designed to survive medical/legal review intact
- Problem-first positioning – narrative restructured around the problem solved and for whom, with mechanism as supporting evidence
- Defensible differentiation – competitive claims built on specific, verifiable comparison points instead of asserted superlatives
Messaging that survives review by saying nothing specific isn't safe – it's just invisible. The sharpest, most specific version of a claim is usually easier to substantiate through review than the vague one, because specificity is what medical and legal reviewers can actually verify.
Our Methodology
We run this as a 90-day sprint built around the two failures that flatten most biotech and pharma messaging: a single script trying to serve four audiences with fundamentally different decision criteria, and a review process treated as an obstacle rather than a design input. The first 30 days are diagnostic – mapping each real audience's decision criteria, auditing current messaging against those criteria, and reviewing what medical, legal, and regulatory review has historically approved versus rejected to understand the real boundaries. Days 30 to 60 build the audience-specific messaging framework and evidence base, working directly with your review team to develop language designed to pass review intact rather than get stripped down after submission. The final 30 days finalize and roll out messaging across channels, with review sign-off built into the process rather than added at the end.
What separates this from a standard brand messaging engagement is that most agencies write one messaging platform and adapt tone lightly by channel, which works for categories with a single buyer but fails badly for biotech and pharma's genuinely distinct audiences. We build separate, evidence-grounded arguments per audience from the start and work inside your review process instead of around it, because for most biotech and pharma companies the messaging problem isn't a lack of creativity – it's that nobody built a framework specific enough to survive review while still being different enough to remember.
How We Work
The first 30 days are audit and mapping. We identify your real distinct audiences and their decision criteria, audit current messaging against those criteria, and review your medical, legal, and regulatory review history to understand what actually gets approved. Days 30 through 60 build the messaging framework and evidence base, working directly with your review team throughout development so language is designed to pass, not submitted cold and stripped down afterward. By day 90 messaging is finalized and rolling out across channels with review sign-off secured.
On our side, the team is a messaging and positioning lead who works directly with your medical, legal, and regulatory reviewers throughout development, not after a first draft is complete. From your side, we need access to your review team early and often, subject matter experts who can validate clinical and competitive claims, and a point of contact who can prioritize review turnaround during the framework development phase.
Cadence is weekly during the first 90 days, covering audience mapping, message development, and review status, with async coordination as review turnaround happens on its own timeline. Typical engagement length is 3 to 4 months for the initial framework and rollout, since building genuinely audience-specific messaging that survives review takes real iteration rather than a single presentation and sign-off.
What to expect at each phase: month one clarifies which audiences actually need distinct arguments and what each one requires to be persuaded. Month two is iterative message development in close coordination with review, often the most intensive phase given how much back-and-forth review-resilient language requires. Month three onward is rollout across channels, with messaging that's already been stress-tested against review rather than requiring a second pass.
- Distinct, audience-specific messaging replacing a single flattened script
- Messaging designed to survive review with differentiation intact
- Positioning reframed around the problem solved, improving clarity for non-specialist audiences
- Defensible competitive differentiation built on verifiable comparison points
If your biotech & pharma company needs brand messaging & positioning leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does a brand messaging engagement cost for a biotech or pharma company?
Most biotech and pharma messaging engagements with us run $10K-20K monthly across the buildout period, depending on how many distinct audiences need separate frameworks and how involved the review process is. That's typically less than a traditional brand agency engagement, and it includes direct coordination with your review team that most agencies leave for the client to manage separately. Companies with more complex multi-audience needs sit toward the higher end.
How long before we see results from a brand messaging engagement?
Audience mapping and diagnostic work typically take the first 3-4 weeks. Message development and review iteration is the longest phase, usually 4-6 weeks given the back-and-forth review requires. Full framework rollout across channels is typically complete by the 90-day mark, though ongoing review sign-off on specific applications continues as new materials are developed.
How does the brand messaging team integrate with our existing staff?
We work directly with your medical, legal, and regulatory reviewers throughout development, not just at final sign-off, and with your marketing and commercial team on rollout across channels. Weekly working sessions cover message development and review status. If you have an in-house brand or marketing team, we become the messaging strategy and review-coordination layer.
What makes Winston Francois different from a traditional brand agency?
Most brand agencies write one messaging platform and adapt tone lightly by channel, an approach that works for a single-buyer category but fails for biotech and pharma's genuinely distinct audiences. We build separate, evidence-grounded messaging per audience and work inside your review process from the start rather than submitting a finished deck cold. We operate as an embedded team accountable to messaging that both differentiates and survives review.
How do you measure ROI from a brand messaging engagement?
We track review approval rate and turnaround time on new messaging, since review-resilient language should move through the process faster with fewer revision cycles. We also assess message recall and differentiation through stakeholder feedback where available, and track whether sales, medical affairs, and investor relations teams are actually using the audience-specific messaging rather than defaulting back to old language.
What type of biotech or pharma company is the right fit for this service?
Companies with genuinely distinct audiences – clinicians, payers, patients, investors – where current messaging tries to serve all of them with one document are the best fit. Companies frustrated that medical, legal, and regulatory review keeps stripping differentiation out of their messaging tend to see the fastest structural improvement. The first step is mapping your specific audiences against what current messaging actually says to each.
